The breakthrough nod covers the use of the stroke detection monitor in the hospital setting. Sunnyvale, California-based Ceribell based its first-in-class offering on its existing hardware. The platform uses an AI-based algorithm to interpret EEG signals for early detection of LVO stroke.
According to a news release, LVO strokes are medical emergencies that carry disproportionately higher morbidity and mortality compared to non-LVO, ischemic stroke. Timely detection and access can lead to significant health benefits over the patient’s lifetime.
Ceribell said the breakthrough nod marks the latest milestone in its effort to expand the uses of its point-of-care EEG brain monitoring technology. It comes on the heels of FDA clearance for a delirium monitoring solution, which came a month after clearance for a next-generation algorithm for monitoring seizures in neonatal patients.
The company’s technology utilizes point-of-care electroencephalography (EEG). It supports more timely, reliable evaluation and continuous monitoring. The system can already support continuous seizure, electrographic status epilepticus (ESE) and delirium monitoring at the bedside.
“Stroke is a devastating condition, but one where quick access to treatment can make a lifetime of a difference,” said Jane Chao, co-founder and CEO of Ceribell. “At a time when minutes matter, patients with in-hospital stroke often experience hours of delay. Ceribell is proud that this FDA breakthrough device designation recognizes the potential of the Ceribell system to provide accurate and timely detection of LVO stroke for this vulnerable patient population.”
This milestone also follows an FDA nod for its seizure algorithm in pediatric patients in 2025. That came shortly after the completion of an initial public offering (IPO) in 2024.
